iShares Global Clean Energy ETF vs Nuvalent Inc — how do they compare? iShares Global Clean Energy ETF trades at $18.57, while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ICLN | NUVL | |
|---|---|---|
52-Week High | $23.75 | $123.96 |
52-Week Low | $13.41 | $72.16 |
Market Cap | — | $9.81B |
Sector | — | Technology |
Enterprise Value | — | $8.52B |
Signals from Pluang's Aura AI — not financial advice
ICLN, the iShares Global Clean Energy ETF, is trading at $18.14, down 1.25% on the day, with a bearish technical outlook. The ETF provides exposure to 105 global renewable energy companies but lacks key valuation metrics like P/E and P/S ratios. Recent news highlights strong 2026 performance with over 25% gains, driven by AI-related power demand and global energy security concerns.
The outlook for ICLN is mixed, balancing strong sector tailwinds against policy risks. Investment opportunities include exposure to the growing clean energy transition, while risks involve US permit delays threatening $121 billion in projects and ongoing comparisons showing higher-yielding alternatives. The technical picture suggests near-term pressure with key support at $18.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Trailing returns across standard periods
Latest headlines on both assets
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →